Inmune Bio, Inc.

This completed Phase 2 study tested whether the drug XPro1595 could help slow cognitive decline in people with early Alzheimer's disease who show signs of brain inflammation. 208 participants with mild Alzheimer's or mild cognitive impairment received either the drug or a placebo…

This early-stage study tested a new cell therapy called INKmune in men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to find the safest and most effective dose and to see how well patients tolerated the tr…